Supplements

← vista completa

Published on September 1, 2008 | http://doi.org/10.5867/medwave.2008.08.1668

Receivers of de novo renal transplant treated with Myfortic, Simulect and reduced exposure to CsA

Receptores de novo de trasplante renal tratados con myfortic, simulect y exposición reducida a CsA

Klemens Budde

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Klemens Budde

Departamento de Nefrología, Hospital y Universidad Charité, Berlín, Alemania

Figures

Article has no figures.

Forum

No messages

History

Citation Budde K. Receivers of de novo renal transplant treated with Myfortic, Simulect and reduced exposure to CsA. Medwave 2008;8(08):e1668 doi: 10.5867/medwave.2008.08.1668

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/09/2008

Index

Metrics

Not available at the moment.

Notes

References

  1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326-33. | CrossRef | PubMed
  2. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001 May 15;71(9):1282-7. | CrossRef | PubMed
  3. Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, et al Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007 Mar;7(3):560-70. Epub 2007 Jan 22. | CrossRef | PubMed
  4. Smak Gregoor PJ, de Sévaux RG, Ligtenberg G, Hoitsma AJ, Hené RJ, Weimar W, Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol. 2002 May;13(5):1365-73. | CrossRef | PubMed
  5. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75. | CrossRef | PubMed
  6. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007 Jun;7(6):1506-14. Epub 2007 Mar 12. | CrossRef | PubMed
  7. Kaplan B, Meier-Kriesche HU, Minnick P, Bastien MC, Sechaud R, Yeh CM, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant. 2005 Aug;19(4):551-8. | CrossRef | PubMed
  8. Budde K, Bosmans JL, Sennesael J, Zeier M, Pisarski P, Schütz M, et al. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. Clin Nephrol. 2007 Mar;67(3):164-75. | PubMed
  9. Frimat L, Cassuto-Viguier E, Charpentier B, Noël C, Provôt F, Rostaing L, et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant. 2006 Nov;6(11):2725-34. | CrossRef | PubMed
  10. Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004 Feb;4(2):237-43. | CrossRef | PubMed
  11. Budde K, Knoll G, Curtis J, Chan L, Pohanka E, Gentil M, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol. 2006 Aug;66(2):103-11. | PubMed
  12. Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation. 2007 Feb 27;83(4):417-24. | CrossRef | PubMed